Search Results - "Benzaïd, Ismahène"

An immunoproteomic approach to characterize the CAR interactome and signalosome by Ramello, Maria C, Benzaïd, Ismahène, Kuenzi, Brent M, Lienlaf-Moreno, Maritza, Kandell, Wendy M, Santiago, Daniel N, Pabón-Saldaña, Mibel, Darville, Lancia, Fang, Bin, Rix, Uwe, Yoder, Sean, Berglund, Anders, Koomen, John M, Haura, Eric B, Abate-Daga, Daniel

“…Adoptive transfer of T cells that express a chimeric antigen receptor (CAR) is an approved immunotherapy that may be curative for some hematological cancers…”
Get more information

Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase by Stresing, Verena, Fournier, Pierrick G, Bellahcène, Akeila, Benzaïd, Ismahène, Mönkkönen, Hannu, Colombel, Marc, Ebetino, F. Hal, Castronovo, Vincent, Clézardin, Philippe

“…Abstract Nitrogen-containing bisphosphonates (N-BPs) are widely used to block bone destruction associated with bone metastasis because they are effective…”
Get full text

High Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Promote Vγ9Vδ2 T-Cell Chemotaxis and Cytotoxicity In Vivo by BENZAID, Ismahène, MÖNKKÖNEN, Hannu, STRESING, Verena, BONNELYE, Edith, GREEN, Jonathan, MÖNKKÖNEN, Jukka, TOURAINE, Jean-Louis, CLEZARDIN, Philippe

“…Abstract The nitrogen-containing bisphosphonate zoledronic acid (ZOL), a potent inhibitor of farnesyl pyrophosphate synthase, blocks the mevalonate pathway,…”
Get full text

In Vivo Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Trigger Vγ9Vδ2 T-cell Antitumor Cytotoxicity through ICAM-1 Engagement by BENZAÏD, Ismahène, MÖNKKÖNEN, Hannu, BONNELYE, Edith, MÖNKKÖNEN, Jukka, CLEZARDIN, Philippe

“…Nitrogen-containing bisphosphonates (N-BP) such as zoledronate and risedronate exhibit antitumor effects. They block the activity of farnesyl pyrophosphate…”
Get full text

Bisphosphonates in preclinical bone oncology: Bisphosphonates by CLEZARDIN, Philippe, BENZAÏD, Ismahène, CROUCHER, Peter I

Get full text

γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer by Frieling, Jeremy S, Tordesillas, Leticia, Bustos, Xiomar E, Ramello, Maria Cecilia, Bishop, Ryan T, Cianne, Junior E, Snedal, Sebastian A, Li, Tao, Lo, Chen Hao, de la Iglesia, Janis, Roselli, Emiliano, Benzaïd, Ismahène, Wang, Xuefeng, Kim, Youngchul, Lynch, Conor C, Abate-Daga, Daniel

“…Immune checkpoint blockade has been largely unsuccessful for the treatment of bone metastatic castrate-resistant prostate cancer (mCRPC). Here, we report a…”
Get full text

Bisphosphonates in cancer therapy by Stresing, Verena, Daubiné, Florence, Benzaid, Ismahène, Mönkkönen, Hannu, Clézardin, Philippe

“…Abstract Bisphosphonates are the standard of care in the treatment of malignant bone diseases, because of their ability to inhibit osteoclast-mediated bone…”
Get full text

Bisphosphonates in preclinical bone oncology by Clézardin, Philippe, Benzaïd, Ismahène, Croucher, Peter I

“…Abstract Bisphosphonates, especially nitrogen-containing bisphosphonates, are widely used to block bone destruction in cancer patients with bone metastasis…”
Get full text

Abstract 1399: Tumor-specific molecular changes in luminal B breast cancer patient-derived xenografts (PDXs) with acquired resistance to endocrine treatment by De Boisferon, Marc Hillairet, Benzaid, Ismahène, Chatel, Elodie Marie Dit, Hoffmann, Nicolas, Littlefield, Bruce A.

“…Abstract Worldwide, numerous preclinical agents that enter oncology clinical trials fail to demonstrate sufficient efficacy in patients to gain regulatory…”
Get full text

Abstract 2826: Examples of translational preclinical models to mimic cancer drug resistance by de Boisferon, Marc Hillairet, Hoffmann, Nicolas, Rajon, Elodie, Benzaid, Ismahène

“…Abstract Drug resistance is becoming a major obstacle when treating patients with cancer. Cancer is characterized by an uncontrolled growth of abnormal cells…”
Get full text

High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo by Benzaïd, Ismahène, Mönkkönen, Hannu, Stresing, Verena, Bonnelye, Edith, Green, Jonathan, Mönkkönen, Jukka, Touraine, Jean-Louis, Clézardin, Philippe

“…The nitrogen-containing bisphosphonate zoledronic acid (ZOL), a potent inhibitor of farnesyl pyrophosphate synthase, blocks the mevalonate pathway, leading to…”
Get full text

High Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Promote V gamma 9V delta 2 T-Cell Chemotaxis and Cytotoxicity In Vivo by Benzaied, Ismahene, Moenkkoenen, Hannu, Stresing, Verena, Bonnelye, Edith, Green, Jonathan, Moenkkoenen, Jukka, Touraine, Jean-Louis, Clezardin, Philippe

“…The nitrogen-containing bisphosphonate zoledronic acid (ZOL), a potent inhibitor of farnesyl pyrophosphate synthase, blocks the mevalonate pathway, leading to…”
Get full text

Abstract 5281: Development of a panel of breast cancer patient-derived xenograft models (PDX) with estrogen independence and/or acquired resistance to endocrine treatment by de Boisferon, Marc Hillairet, Benzaid, Ismahene, Chatel, Elodie Marie Dit, Hoffmann, Nicolas, Littlefield, Bruce

“…Abstract Eighty five percent of preclinical agents entering oncology clinical trials fail to demonstrate sufficient safety or efficacy to gain regulatory…”
Get full text

In Vivo Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Trigger V gamma 9V delta 2 T-cell Antitumor Cytotoxicity through ICAM-1 Engagement by Benzaid, Ismahene, Monkkonen, Hannu, Bonnelye, Edith, Monkkonen, Jukka, Clezardin, Philippe

“…Purpose: Nitrogen-containing bisphosphonates (N-BP) such as zoledronate and risedronate exhibit antitumor effects. They block the activity of farnesyl…”
Get full text

Abstract 934: γδ CAR T-cell therapy significantly mitigates bone metastatic castrate-resistant prostate cancer by Frieling, Jeremy Steven, Ramello, Maria Cecilia, Benzaid, Ismahene, Roselli, Emiliano, Lo, Chen Hao, Lynch, Conor C., Abate-Daga, Daniel

“…Abstract Bone metastasis is a frequent complication in advanced prostate cancer, with the resultant lesions significantly contributing to patient morbidity and…”
Get full text

Frequent Intermittent Low-dose Therapy Accentuates the Antitumour Activity of the Bisphosphonate Risedronate In Vivo by Stresing, Verena, Deux, Blandine, Benzaid, Ismahene, Mathevet, Patrice, Ebetino, Hal, Clézardin, Philippe

Get full text

Zoledronate-Induced IPP/ApppI (Phosphoantigen) Accumulation in Human Breast Cancer Cells Correlates with Vγ9VΔ2 T Cell-Mediated Cancer Cell Death In Vitro and In Vivo by Benzaid, Ismahene, Mönkkönen, Hannu, Stresing, Verena, Bonnelye, Edith, Green, Jonathan, Mönkkönen, Jukka, Clézardin, Philippe

Get full text

Zoledronic acid induces IPP release from cancer cells which causes Vgamma9Vdelta2 T cell expansion in PBMCs by Arkko, Satu, Mönkkönen, Jukka, Auriola, Seppo, Dronda, Irene Rosell, Benzaid, Ismahene, Stresing, Verena, Clezardin, Philippe, Mönkkönen, Hannu

Get full text

P49. Zoledronic acid-induced IPP accumulation in cancer cells strongly correlates with γδ T-cell mediated cancer cell death by Monkkonen, Hannu, Benzaid, Ismahene, Stresing, Verena, Green, Jonathan, Monkkonen, Jukka, Touraine, Jean-Louis, Clezardin, Philippe

Get full text

Zoledronic acid-induced IPP accumulation in cancer cells strongly correlates with gammadelta T-Cell mediated cancer cell death by Monkkonen, Hannu, Benzaid, Ismahene, Stresing, Verena, Green, Jonathan, Monkkonen, Jukka, Touraine, Jean L, Clezardin, Philippe

Get full text